Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Deborah M. Stephens, Hongli Li, Heiko Scho¨der, David J. Straus, Craig H. Moskowitz, Michael LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Ann S. LaCasce, Paul M. Barr, Michael V. Knopp, Eric D. Hsi, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)- adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET22 and PET21 patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET22 patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.

Original languageEnglish (US)
Pages (from-to)1238-1246
Number of pages9
JournalBlood
Volume134
Issue number15
DOIs
StatePublished - Oct 10 2019

Fingerprint

Positron emission tomography
Bleomycin
Hodgkin Disease
Positron-Emission Tomography
Doxorubicin
Procarbazine
Dacarbazine
Vinblastine
Poisons
Vincristine
Etoposide
Prednisone
Cyclophosphamide
Disease-Free Survival
Confidence Intervals
Second Primary Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Stephens, D. M., Li, H., Scho¨der, H., Straus, D. J., Moskowitz, C. H., LeBlanc, M., ... Friedberg, J. W. (2019). Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 134(15), 1238-1246. https://doi.org/10.1182/blood.2019000719

Five-year follow-up of SWOG S0816 : Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. / Stephens, Deborah M.; Li, Hongli; Scho¨der, Heiko; Straus, David J.; Moskowitz, Craig H.; LeBlanc, Michael; Rimsza, Lisa M.; Bartlett, Nancy L.; Evens, Andrew M.; LaCasce, Ann S.; Barr, Paul M.; Knopp, Michael V.; Hsi, Eric D.; Leonard, John P.; Kahl, Brad S.; Smith, Sonali M.; Friedberg, Jonathan W.

In: Blood, Vol. 134, No. 15, 10.10.2019, p. 1238-1246.

Research output: Contribution to journalArticle

Stephens, DM, Li, H, Scho¨der, H, Straus, DJ, Moskowitz, CH, LeBlanc, M, Rimsza, LM, Bartlett, NL, Evens, AM, LaCasce, AS, Barr, PM, Knopp, MV, Hsi, ED, Leonard, JP, Kahl, BS, Smith, SM & Friedberg, JW 2019, 'Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma', Blood, vol. 134, no. 15, pp. 1238-1246. https://doi.org/10.1182/blood.2019000719
Stephens, Deborah M. ; Li, Hongli ; Scho¨der, Heiko ; Straus, David J. ; Moskowitz, Craig H. ; LeBlanc, Michael ; Rimsza, Lisa M. ; Bartlett, Nancy L. ; Evens, Andrew M. ; LaCasce, Ann S. ; Barr, Paul M. ; Knopp, Michael V. ; Hsi, Eric D. ; Leonard, John P. ; Kahl, Brad S. ; Smith, Sonali M. ; Friedberg, Jonathan W. / Five-year follow-up of SWOG S0816 : Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. In: Blood. 2019 ; Vol. 134, No. 15. pp. 1238-1246.
@article{168dbe373eb6467e98642ab5edf9f70c,
title = "Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma",
abstract = "Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)- adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82{\%} and positive in 18{\%}. For all patients, the estimated 5-year PFS and OS was 74{\%} (95{\%} confidence interval [CI], 69{\%}-79{\%}) and 94{\%} (95{\%} CI, 91{\%}-96{\%}), respectively. For PET22 and PET21 patients, the 5-year PFS was 76{\%} (95{\%} CI, 70{\%}-81{\%}) and 66{\%} (95{\%} CI, 52{\%}-76{\%}), respectively. Seven (14{\%}) and 6 (2{\%}) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25{\%} of PET22 patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.",
author = "Stephens, {Deborah M.} and Hongli Li and Heiko Scho¨der and Straus, {David J.} and Moskowitz, {Craig H.} and Michael LeBlanc and Rimsza, {Lisa M.} and Bartlett, {Nancy L.} and Evens, {Andrew M.} and LaCasce, {Ann S.} and Barr, {Paul M.} and Knopp, {Michael V.} and Hsi, {Eric D.} and Leonard, {John P.} and Kahl, {Brad S.} and Smith, {Sonali M.} and Friedberg, {Jonathan W.}",
year = "2019",
month = "10",
day = "10",
doi = "10.1182/blood.2019000719",
language = "English (US)",
volume = "134",
pages = "1238--1246",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Five-year follow-up of SWOG S0816

T2 - Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

AU - Stephens, Deborah M.

AU - Li, Hongli

AU - Scho¨der, Heiko

AU - Straus, David J.

AU - Moskowitz, Craig H.

AU - LeBlanc, Michael

AU - Rimsza, Lisa M.

AU - Bartlett, Nancy L.

AU - Evens, Andrew M.

AU - LaCasce, Ann S.

AU - Barr, Paul M.

AU - Knopp, Michael V.

AU - Hsi, Eric D.

AU - Leonard, John P.

AU - Kahl, Brad S.

AU - Smith, Sonali M.

AU - Friedberg, Jonathan W.

PY - 2019/10/10

Y1 - 2019/10/10

N2 - Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)- adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET22 and PET21 patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET22 patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.

AB - Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)- adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET22 and PET21 patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET22 patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.

UR - http://www.scopus.com/inward/record.url?scp=85074420867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074420867&partnerID=8YFLogxK

U2 - 10.1182/blood.2019000719

DO - 10.1182/blood.2019000719

M3 - Article

C2 - 31331918

AN - SCOPUS:85074420867

VL - 134

SP - 1238

EP - 1246

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -